What is happening at Ardena – new capabilities, new partnerships, new science. Everything that moves Ardena forward.
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote. The launch responds to a recurring need among sponsors: confirming early whether a provider has experience with a given biomarker, on which platform and in which matrix and species, before committing samples and […]
Ghent, Belgium – 02/10/2026 – Ardena has installed a STYL’ONE Evo Compaction Simulator from Medelpharm (KORSCH Group) at its drug product site in Ghent (Belgium). The investment strengthens Ardena’s oral solid dosage development capabilities and enables its formulation scientists to predict, from the earliest development stages, how a tablet formulation will perform at commercial scale. […]
Following a collaboration that started in 2021, Ardena is proud to see Kupando reach a key milestone with the first patient dosed in the Phase 1 clinical study of KUP101, its lead candidate for the treatment of advanced solid tumors. Kupando has announced the successful dosing of the first patient in the Phase 1 clinical study of KUP101, a differentiated […]
This October, Ardena is putting every step at CPHI Worldwide towards a good cause. Alongside our planned business activities at CPHI Worldwide 2026 in Milan (October 6–8), we will be launching a charity step challenge at Booth 10F1, inviting attendees to pick up a step tracker watch, take part in the daily challenge, and help turn the many steps taken across the show floor into […]
Assen, Oss and Leiden, the Netherlands, June 10, 2026 – Over the last 15 years, Ardena and the Centre for Human Drug Research (CHDR) have combined GLP-accredited bioanalytical capabilities with clinical pharmacology expertise to support early phase drug development programs where speed, sample integrity and scientific precision are critical. Working across CHDR’s early clinical development operations in Leiden and Ardena’s bioanalytical laboratories […]
Ghent, Belgium, June 1, 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief Scientific Officer. This reflects Ardena’s continued focus on scientific excellence across its integrated offering, supporting customers from early development through to later-stage clinical and […]
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and […]
Somerset, New Jersey, USA – April 15, 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new state-of –the-art bioanalytical laboratory in Somerset, New Jersey, is now operational and supporting client studies. The 2,500+ sqft laboratory expands Ardena’s scientific capabilities in North America and provides […]
Ghent, Belgium, April 1, 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces its contribution to the advancement of CYRS1542, a novel GSPT1 molecular glue degrader developed by Cyrus Therapeutics, into Phase 1 clinical development. Cyrus Therapeutics received Investigational New Drug (IND) approvals from both the US […]
Ghent, Belgium, 10th March 2026 – PharmaResearch, headquartered in Seongnam, South Korea, has recently received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of PRD-101, a nano-based anticancer drug candidate. The authorization marks a significant milestone in advancing PRD101 into […]
Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth. Paul brings over 30 years of Human Resources leadership experience in complex, science-driven […]
Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary within the Nanologica Group and will […]
